The Online Investor
Daily M&A
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Mega-Mergers: Largest Recent M&A Transactions

By The Online Investor Staff, updated Sat., Jan. 31, 5:33 PM

Slide #1. Mylan Inc. Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business

Acquirer: Mylan Inc. (MYL)
Acquiree: Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business (ABT)
Details: Mylan Inc. (Nasdaq: MYL) announced that at a Special Meeting of Shareholders held Jan. 29, 2015, Mylan's shareholders overwhelmingly approved the agreement implementing Mylan's pending acquisition of Abbott's (NYSE: ABT) non-U.S. developed markets specialty and branded generics business and reorganization in the Netherlands in an all-stock transaction. The agreement implementing the transaction received the approval of approximately 98% of the votes cast and the advisory vote on the proposal regarding certain compensation matters related to the transaction received the approval of approximately 82% of the votes cast.

Mylan and its subsidiaries are engaged in the global development, licensing, manufacture, marketing and distribution of generic, brand and branded generic pharmaceutical products for resale by others and active pharmaceutical ingredients through two segments, Generics and Specialty. The principal markets for Generics are proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and health care institutions primarily in the U.S.

Open the MYL Page at The Online Investor »

Mylan and its subsidiaries are engaged in the global development, licensing, manufacture, marketing and distribution of generic, brand and branded generic pharmaceutical products for resale by others and active pharmaceutical ingredients through two segments, Generics and Specialty. The principal markets for Generics are proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and health care institutions primarily in the U.S.

Open the ABT Page at The Online Investor »

Company Name:  Mylan Inc
Website:  www.mylan.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding MYL:  77
Total Market Value Held by ETFs:  $1.54B
Total Market Capitalization:  $21.07B
% of Market Cap. Held by ETFs:  7.33%
Company Name:  Abbott Laboratories
Website:  www.abbott.com
Sector:  Medical Instruments & Supplies
Number of ETFs Holding ABT:  82
Total Market Value Held by ETFs:  $3.10B
Total Market Capitalization:  $65.77B
% of Market Cap. Held by ETFs:  4.71%
 

January 31, 2015    5:33 PM Eastern
Quotes delayed 20 minutes


Mega-Mergers | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.